glp 1 injections tirzepatide FDA approval for Zepbound (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly FDA says shortage of GLP-1

Results develop gradually over 2-3 months as new collagen forms, and they continue to improve for up to six months

Rotate injection points to avoid repeated use of the same spot

Similarly, in a pilot randomised trial for binge-eating disorder, liraglutide produced greater weight loss than placebo, but reductions in objective binge episodes and binge remission did not differ significantly between groups, suggesting that weight loss and binge-eating improvement may not always change in parallel (105)

They also act on the appetite centers in the brain, significantly reducing hunger and what is often called food noise. The dual-action drug tirzepatide works on both GLP-1 and GIP receptors, often leading to even greater efficacy